Study agents | Other agents | Disease | No Pts | Response | Reference |
---|---|---|---|---|---|
Sorafenib | Decitabine | Relapsed Refractory | 6 | OR 83% CR 80% | [17] |
Sorafenib | 5-azacytidine | Relapsed | 43 | OR 46% | [18] |
Sorafenib | Daunorubicin Cytarabine | Untreated | 54 | 1-year OS 62% DFS 12.2 months OS 15 months | [20] |
Sorafenib | Daunorubicin Cytarabine | Untreated | 267 | EFS 21 months 3-year EFS 40% | [21] |